… with the promotion of mammalian target of rapamycin (mTOR) and … neural flexibility in key
limbic regions, allowing for a … the mTOR pathway mediates ketamine’s antidepressant effects (…

… target of rapamycin (mTOR), mitogen-activated protein kinases (MAPK) or glycogen synthase
kinase 3 (GSK-3)… Likewise, ketamine has been reported to activate mTOR and downstream …

… 92,93 and because ketamine evokes antidepressive effects, we … We did not aim to assess
how the chronic stress affects LTP … In particular, our results revealed the possible role of GSK-3-…

… the antidepressant action of various NMDA antagonists … target through which the
antidepressant effects of ketamine … indirect NMDAR inhibition via regulation of serine racemase …

… Other AMPA-targeted agents in different stages of the drug … high-throughput screening
format by assaying CREB-mediated β-… Glycogen synthase kinase-3 (GSK-3) is a multifunctional …

… are directly involved in immunity regulation [73]. Lithium’s … mediate intracellular calcium levels,
which are regulated by SNP. … The protein and mRNA expression of GSK-3 β in the DLPFC …

… as a possible candidate for regulating excitatory receptors such as AMPA and NMDA. …
in better performance on cognitive tasks. Aim 1 addressed the effect on behavior, while Aim 2 …

… MK801 and ketamine selectively enhanced the mobility of … NMDAR are a promising target
for the treatment of diabetes (… CK2 is a constitutively active kinase, but it mediates regulation of …

… can be targeted for effective management of disease state. … /exercise positively affects the
cognition performance of older … and biological pathways in regulating proteostasis control, …

… NMDA receptor (NMDAR) antagonist esketamine (the S-isomer of … ketamine effects on
potential targets/pathways linked to MDD, including AMPA receptor, the mammalian target of …